3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
12
Other hematologic neoplasm
5
Lymphoid
4
Gastrointestinal
4
Dermatologic
4
Plasma cell
3
Myeloid
2
Tumor-Agnostic
1
Thoracic
1
Other
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Classical hematology
1
CNS
1
Conditions
Obesity
1
Inflammation
1
Breast Neoplasms
1
Interventions
Radiotherapy
5
Surveys and Questionnaires
4
Cisplatin
4
angiotensin I (1-7)
3
alvimopan
3
Radiation
3
Injections
3
Water
2
Vitamin D
2
Tirzepatide
2
RRx-001
2
Mouthwashes
2
Metformin
2
Interleukin 1 Receptor Antagonist Protein
2
High-Intensity Focused Ultrasound Ablation
2
Drug Therapy
2
Dexmedetomidine
2
Dexamethasone
2
Calcium Dobesilate
2
Amifostine
2
Acetylcysteine
2
tempol
1
peppermint oil
1
pegfilgrastim
1
naloxegol
1
methylnaltrexone
1
methyl N-acetylsibirosaminide
1
linaclotide
1
licogliflozin
1
kang-lai-te
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tablets
×
Other
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled